Evidence map›Paper›PMID 41424914›Full record

ArticleAPL bioengineering2025

Tissue regenerative medicine: Clinical advances, challenges, and opportunities.

Seleem Badawy, Varshiny Gopinath, Ana M Diaz Espinosa, Kasinan Suthiwanich, Ethan C Kelmser, Victoria Duke, Veda Kamaraju, Karina Nakayama, Manoj Manna, Julianne J-Y Liu and 3 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in APL bioengineering, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Seleem BadawyORCID https://orcid.org/0000-0002-7985-4628
Varshiny GopinathDepartment of Urology, University of California San Diego Medical Center, San Diego, California 92121, USA.ORCID https://orcid.org/0009-0002-8424-0126
Ana M Diaz EspinosaDepartment of Biomedical Engineering and Physiology, Mayo Clinic, Rochester, Minnesota 55905, USA.ORCID https://orcid.org/0000-0002-2387-1429
Kasinan SuthiwanichToronto General Hospital Research Institute, University Health Network, Toronto, Ontario M5G 2C4, Canada.ORCID https://orcid.org/0000-0003-3653-5050
Ethan C KelmserDepartment of Biomedical Engineering, Oregon Health & Science University, Portland, Oregon 97239, USA.
Victoria DukeDepartment of Biomedical Engineering, Oregon Health & Science University, Portland, Oregon 97239, USA.ORCID https://orcid.org/0000-0001-6949-1862
Veda KamarajuDepartment of Biomedical Engineering, Cornell University, Ithaca, New York 14853, USA.ORCID https://orcid.org/0009-0004-9794-2826
Karina NakayamaDepartment of Biomedical Engineering, Oregon Health & Science University, Portland, Oregon 97239, USA.
Manoj MannaDepartment of Materials Sciences, Stanford University, Stanford, California 94305, USA.ORCID https://orcid.org/0000-0003-1469-6494
Julianne J-Y LiuDepartment of Cardiothoracic Surgery, Stanford University, 300 Pasteur Drive, MC 5407, Stanford, California 94305, USA.ORCID https://orcid.org/0009-0007-9694-9489
Sara S NunesORCID https://orcid.org/0000-0003-0906-7204
Keyue ShenDepartment of Biomedical Engineering, University of Southern California, Los Angeles, California 90089, USA.ORCID https://orcid.org/0000-0001-9605-1635
Ngan F HuangORCID https://orcid.org/0000-0003-2298-6790

Funding

Development of a Bioengineered Therapeutic Device for the Prevention of LymphedemaR01CA285372 · NCI · PALO ALTO VETERANS INSTIT FOR RESEARCH · PI Ngan F. Huang, Michael Vitoldovich Paukshto · 2024 to 2026
$1.6M
Biomaterials for delivery and maintenance of tip endothelial cellsR21HL172096 · NHLBI · UNIVERSITY OF CALIFORNIA, MERCED · PI HUANG, NGAN F., MCCLOSKEY, KARA E · 2024 to 2025
$643k
Enhance Cell Therapies for Peripheral Arterial Disease Using Human-Compatible Protease-Based ControlsR21HL177570 · NHLBI · STANFORD UNIVERSITY · PI GAO, XIAOJING J, HUANG, NGAN F. · 2025 to 2025
$410k
Novel Highly Regenerative and Scalable Progenitor Cell Exosomes for Treating Peripheral Artery DiseaseR41HL170875 · NHLBI · SERINA THERAPEUTICS, INC. · PI HUANG, NGAN F., LEE, JI EUN · 2023 to 2023
$341k
BLRD VA I01 BX004259BLRD VA I01 BX006882BLRD VA IK6 BX006309NCI NIH HHS R01 CA285372NHLBI NIH HHS R21 HL172096NHLBI NIH HHS R21 HL177570NHLBI NIH HHS R41 HL170875
6 · The paper itself

Abstract

Regenerative medicine is transforming how we restore tissue function, leveraging advances in cell and molecular biology, biomaterials, and engineered microenvironments. While there have been notable advances and rapid progress over the past few decades, ongoing challenges persist in the technical development and effective translation of these advancements to clinical care. This perspective highlights clinically promising examples and critically assesses present challenges in translating tissue regenerative medicine therapies from the bench to the clinic. We further examine the evolving landscape of regenerative medicine by describing strategies to optimize the cellular microenvironment, the impact of patient demographics, and the use of artificial intelligence to shape the future of this field.

Identifiers

PMID41424914
PMCPMC12716889

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.